Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00716976 · OUTCOME

Event-Free Survival (EFS)

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy · Source last updated 2023-11-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage probability
Interval / dispersion
95% Confidence Interval
Time frame
4 years after enrollment

What was measured

Proportion of patients event free at 4 years following enrollment. See EFS outcome measure description.

Analysis population: 61 eligible patients were enrolled on the STS arm; 64 eligible patients were enrolled on the observation arm.

Groups in this outcome

STS Arm (Sodium Thiosulfate Treatment)

Sodium thiosulfate treatment.

Observation Arm

No sodium thiosulfate treatment.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
STS Arm (Sodium Thiosulfate Treatment)61
Observation Arm64

Reported measurements

Source class 1
Values in Percentage probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
STS Arm (Sodium Thiosulfate Treatment)53.7Not reported39.865.8Not reported
Observation Arm61.4Not reported48.072.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        39.8
        upper Limit
        65.8
        value
        53.7
      2. group Id
        OG001
        lower Limit
        48.0
        upper Limit
        72.3
        value
        61.4
denoms
  1. counts
    1. group Id
      OG000
      value
      61
    2. group Id
      OG001
      value
      64
    units
    Participants
description
Proportion of patients event free at 4 years following enrollment. See EFS outcome measure description.
dispersion Type
95% Confidence Interval
groups
  1. description
    Sodium thiosulfate treatment.
    id
    OG000
    title
    STS Arm (Sodium Thiosulfate Treatment)
  2. description
    No sodium thiosulfate treatment.
    id
    OG001
    title
    Observation Arm
param Type
NUMBER
population Description
61 eligible patients were enrolled on the STS arm; 64 eligible patients were enrolled on the observation arm.
reporting Status
POSTED
time Frame
4 years after enrollment
title
Event-Free Survival (EFS)
type
SECONDARY
unit Of Measure
Percentage probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice